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Asparagine Endopeptidase Can Initiate the Removal
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cells treated with a cathepsin S (catS) inhibitor (Riese
et al., 1996) or with catS deficient APCs (Nakagawa et
al., 1999; Shi et al., 1999) indicate that catS is criticallySummary
involved in generating CLIP in bone marrow-derived
professional APCs. In contrast, cathepsin L (catL) medi-The invariant chain (Ii) chaperone for MHC class II
ates the same late stage of Ii degradation in corticalmolecules is crucial for their effective function. Equally
thymic epithelial cells (Nakagawa et al., 1998). In theimportant is its removal. Cathepsins S or L are known
absence of these activities an N-terminal fragment ofto be required for the final stages of Ii removal in differ-
approximately 10 kDa, referred to as p10, accumulatesent APCs, but the enzymes which initiate Ii processing
on MHC class II. An additional protease, cathepsin F,have not been identified. Here we show that this step
expressed in macrophages can substitute for the func-can be performed in B lymphocytes by asparagine
tion of catS and catL in CLIP formation (Shi et al., 2000).endopeptidase (AEP), which targets different aspara-
The enzyme(s) that generate the p10 intermediate is notgine residues in the lumenal domain of human and
known but a similarly sized intermediate accumulatesmouse invariant chain. Inhibition of AEP activity slows
in the presence of the broad spectrum cysteine proteaseinvariant chain processing and hinders the expression
inhibitor leupeptin (Amigorena et al., 1995). In human Bof an antigenic peptide engineered to replace the
lymphoblastoid cells, leupeptin induces the accumula-groove binding region of Ii (CLIP). However, the initia-
tion of a larger intermediate of 22 kDa (Blum and Cress-tion of Ii removal can also be performed by other prote-
well, 1988; Nguyen et al., 1989) known as LIP (leupeptin-ases, reflecting the importance of this step.
induced peptide). This blockage of Ii processing leads
to a decrease in class II expression at the cell surfaceIntroduction
(Neefjes and Ploegh, 1992; Brachet et al., 1997). The
fact that processing of Ii still occurs in the presence of
During biosynthesis, major histocompatibility complex broad specificity cysteine protease inhibitors shows that
(MHC) class II molecules associate with the invariant another as yet unidentified enzyme or enzymes can initi-
chain (Kvist et al., 1982), a type II membrane protein, ate Ii processing. It has generally been assumed that
which performs three main chaperone functions (re- this step was performed by a noncysteine protease.
viewed in Sant and Miller, 1994; Cresswell, 1994; Stumpt- Asparagine endopeptidase (AEP) or mammalian le-
ner-Cuvelette and Benaroch, 2002). First, the invariant gumain is an asparagine-specific cysteine protease that
chain (Ii) associates as a homotrimer with three  het- has been recently implicated in the MHC class II path-
erodimers of MHC class II to form a nonameric structure way. AEP has been shown to initiate processing of the
(Roche et al., 1991; Lamb and Cresswell, 1992). Second, tetanus toxin antigen in B cells (Manoury et al., 1998;
by interacting tightly with the MHC class II groove, it Antoniou et al., 2000; Watts, 2001) and has recently been
inhibits the loading of peptides generated in the ER shown to be capable of destroying an immunodominant
(Roche and Cresswell, 1991; Bijlmakers et al., 1994a; peptide of myelin basic protein (MBP, 85-99), an autoan-
Busch et al., 1996) and at the same time stabilizes the tigen implicated in the inflammatory demyelinating dis-
nonameric complex (Zhong et al., 1996). This interaction ease multiple sclerosis (Manoury et al., 2002). Thus, AEP
occurs via residues 81–104 of its lumenal domain (Ro- can have both positive and negative effects on the out-
come of antigen processing. AEP is unrelated to the
papain-like cysteine proteases such as cathepsins S*Correspondence: b.manoury@dundee.ac.uk (B.M), c.watts@dundee.
ac.uk (C.W.) and L and instead is grouped together with the cas-
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Figure 1. Digestion of 35S-Labeled Class II/Ii
Complexes with Disrupted Lysosomes or Pu-
rified AEP
(A and B) 35S-Met/Cys labeled class II/Ii com-
plexes were immunoprecipitated (EDR cells)
with DA6.231 mAb and digested with EBV-B
cell lysosomal fractions (5 g) in the absence
or presence of the indicated inhibitors. The
reactions were separated on a 12% Bis-Tris
Nupage gel. Track 6 shows inefficient degra-
dation of class II/Ii complexes with disrupted
lysosomes from the HL-60 monocytic cell
line.
(C) 35S-Met/Cys-labeled murine Ii chain
(LB27.4 cells) was immunoprecipitated with
the IN1 mAb and digested with increasing
amounts of purified pig kidney AEP for 1 hr.
Digestion products were analyzed on a 12%
Bis-Tris Nupage gel.
(D) As in (C), but human class II/Ii complexes
were immunoprecipitated with DA6.231 mAb.
10 mU of AEP was used to digest the com-
plexes in vitro.
pases, separase, and some bacterial proteases in clan but which also blocks AEP (Alvarez-Fernandez et al.,
1999), was a much more effective inhibitor of Ii degrada-CD (Chen et al., 1998). It is unique among lysosomal
cysteine proteases in that it is insensitive to E-64 and tion (Figure 1A, track 4). To investigate this further, we
used the F-moc-Ala-Glu-Asn-Lys-NH2 (AENK) tetrapep-leupeptin (Chen et al., 1997; Manoury et al., 1998). Be-
cause the initial step of degradation of Ii has been shown tide, previously described to specifically inhibit AEP
(Manoury et al., 1998). AENK together with leupeptinto be leupeptin insensitive, we investigated the possible
role of AEP in this process. showed a clear inhibition of Ii chain degradation (Figure
1B, track 4) whereas, in contrast, no inhibition was ob-Here we show that intact Ii is a substrate for AEP both
in vitro and in living cells. Blocking AEP activity either served with the control peptide AEQK (Figure 1B, track
5). Furthermore, lysosomes purified from the primaryby mutating the AEP cleavage sites in the Ii chain or by
use of a specific AEP inhibitor delays the appearance monocytic cell line, HL-60, which lacks AEP activity
(B.M, unpublished data) but expresses other cysteineof the p10 and p22 intermediate fragments in murine
and human B cells, respectively. Finally, when the CLIP proteases, digested the Ii chain poorly (Figure 1B, track
region of the Ii chain is replaced by flu HA 306-318, loss 6). These results suggested that, in vitro, AEP makes a
of AEP processing sites adversely affects presentation significant contribution to Ii processing by B cell lyso-
of HA to T cells. Our data suggest that AEP plays an somes.
important but not exclusive role in initiating Ii processing
in living cells.
AEP Processing Sites in the Ii Chain
To identify asparagine residues targeted by AEP on theResults
Ii chain, Ii molecules from mouse B cells were labeled
with 35S-Cys/Met, immunoprecipitated, and incubatedLysosomal Proteases Involved in Ii Chain
with purified AEP. Several cleavage products were gen-Processing In Vitro
erated depending on the amount of protease addedTo analyze the processing of the Ii chaperone molecule
during the digestion (Figure 1C). Similar results werein vitro, we incubated radiolabeled MHC class II /Ii chain
obtained when MHC class II-Ii chain complexes fromcomplexes with lysosomes isolated from the human Ep-
human B cells were used as substrates for AEP digestionstein-Barr virus (EBV)-transformed B cell lines EDR or
(Figure1D). AEP cleavage products from human andPALA. The main p31 isoform and the splicing variant
mouse Ii chains were radiosequenced by Edman degra-p41 form of the Ii chain were digested to produce a
dation. We could identify a predominant cleavage prod-discrete pattern of bands at mildly acidic pH (e.g., Figure
uct from the mouse Ii chain consistent with a cleavage1A, track 2) whereas the  and  chains of MHC class
after Asn105 localized just downstream of the CLIP pep-II were comparatively resistant. We then used various
tide. In human Ii, radiosequencing indicated two pre-protease inhibitors to identify the enzymes involved in
dominant cleavages after Asn76 and 155. We also ob-Ii degradation in vitro. As shown in Figures 1A and 1B,
served a cleavage at Asn11, but this is in the cytoplasmicleupeptin had relatively little effect on p31 degradation
tail and so cannot be relevant to Ii processing in livingconsistent with in vivo data showing that Ii processing
cells (data not shown). These results demonstrate thatstill proceeds in its presence (Blum and Cresswell, 1988).
Asn105 for mouse Ii and Asn155 for human Ii as well asIn contrast, addition of cystatin C which, like leupeptin,
blocks the cysteine proteases from the papain family Asn76 for human Ii can be recognized by AEP in vitro.
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MHC class II/Ii chain complexes were then immunopre-
cipitated with the Y3P antibody. As expected, the p10
fragment of wild-type Ii chain (N) appeared after 1 hr of
chase in the presence of leupeptin and accumulated
progressively thereafter (Figure 3A). (Note that the signal
increases between 2 and 3 hr of chase because theY3P
antibody preferentially recognizes mature forms of MHC
class II). In contrast, we observed a clear delay in p10
formation when the mutated Ii chain (N105, 153, 159,
178Q) was expressed in COS cells (Figures 3A and 3B).
Low levels of p10 were made from the mutant Ii after 1 hr
of chase in the presence of leupeptin and still remained
lower than wild-type even at 4 hr. Interestingly, we ob-
served instead a small but distinct accumulation of
higher molecular weight products (* in Figure 3A). SimilarFigure 2. Schematic Representation of Potential AEP Processing
results were obtained when processing of mutated andSites in the Mouse and Human Ii Chain Protein
wild-type Ii was examined in Chinese hamster ovaryThe vertical box represents the lipid bilayer, and the black bar shows
the trimerization domain. Lollipop symbols indicate where Asn sites cells (CHO) transfected with  and  chains of the H-2d
are located in the human (top) and mouse (bottom) invariant chain. class II haplotype (data not shown). Mutating N105 alone
Asn residues upstream (N-terminal) of CLIP are not shown. Residues also delayed the appearance of p10, but the effect was
targeted by AEP which could potentially generate mouse p10 and less dramatic (data not shown and see Discussion).
human p22 fragments are shown in bold. Distances are not to scale.
We then performed similar experiments in the ab-
sence of leupeptin to assess the rate of processing of
the wild-type or mutated Ii p31 when all proteases wereOther Asn residues may well be targeted by AEP but may
active. Radiolabeled MHC class II/Ii chain complexesnot be easily identified by radiosequencing techniques.
were first immunoprecipitated with M5/114 antibody
and then reimmunoprecipitated using the IN1 antibody.
Mutating AEP Cleavage Sites Delays Murine Figure 3C shows that at early times of chase, the mu-
Ii Processing in Living Cells tated Ii (Q) was less susceptible to degradation com-
The two AEP processing sites downstream of CLIP pared to the WT Ii (N). Quantification of these results
could potentially generate the p10 and p22 Ii products showed after 2 hr of chase a significant difference in
induced by leupeptin in mouse and human Ii chain, re- the amount of the full-length p31 Ii chain remaining when
spectively, as shown in Figure 2. To establish whether AEP sites were missing (wild-type Ii, 7.7%; mutated Ii
AEP could generate the p10 intermediate product in chain, 40%, Figure 3D). Taken together, these results
living cells, site-directed mutagenesis was performed demonstrate that mutating AEP cleavage sites delays Ii
on AEP cleavage sites in the mouse Ii. Asparagine resi- processing in living cells.
due 105 was mutated to Gln along with three potential
downstream cleavage sites (153, 159, and 178) some of
which we had identified as AEP targets in the human Ii. AEP Overexpression Boosts the Appearance
of the p22 Intermediate Ii Processing ProductWild-type (N) or mutated (Q) Ii cDNA was cotransfected
together with cDNA for the  and  chains of the MHC The above results suggested that increasing expression
of AEP might accelerate Ii processing. To test this, weclass-II H-2 b haplotype into COS cells. Forty-eight hours
later, the COS cells were labeled with 35S-Cys/Met and established MelJuSo cell lines in which overexpression
of AEP is under the control of tetracycline or doxycyclinechased for different times in the presence of leupeptin.
Figure 3. Mutating AEP Cleavage Sites on
Murine Ii Chain Slow Down Its Processing
(A) Wild-type (N) or mutated (N105, 153, 159,
178Q) murine Ii chain cDNAs were transiently
transfected into COS cells together with Ab
 and Ad  cDNAs. Forty-eight hours after
transfection, the cells were labeled with
35S-Met/Cys and chased for different times in
the presence of leupeptin (1 mM). Class II/Ii
complexes were immunoprecipitated with
mAb Y3P and analyzed by 12% SDS-PAGE.
(B) Quantification of the experiment shown in
(A).
(C) As in (A), but the chase was in the absence
of leupeptin, and Ii molecules were reimmu-
noprecipitated with the IN1 mAb from M5/
114-classII/Ii precipitates.
(D) Quantification of the experiment in (C).
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Figure 4. Overexpression of AEP Accelerates Ii Processing
(A) Control (Dox) and AEP overexpressing (Dox) MelJuSo cells were labeled with 35S Met/Cys and chased for different times. Ii molecules
were reimmunoprecipitated with VIC-Y1 mAb from DA6.231-class II/Ii precipitates. Samples were analyzed by 14% SDS-PAGE.
(B) Quantification of the experiment in (A). Note that the additional product around 7 kDa generated under conditions of AEP overexpression
was not consistently seen in all experiments.
using the Tet-Off system. A clone of the cell line MelJuSo NHmec or Z-Phe-Arg-NHmec preferred by cathepsin S
and cathepsins B/L, respectively (Figure 5A). Con-was generated that expresses normal amounts of AEP
in the presence of doxycycline, but upon removal of the versely, leupeptin and LHVS treatment blocked hydroly-
sis of the catB/L and catS substrates but not the AEPdrug an approximately 10-fold increase in AEP activity
is induced (Manoury et al., 2002). To assess the kinetics substrate (Figure 5A). To provide independent confirma-
tion that MV026630 did not react with other cysteineof Ii degradation in the overexpressing and control Mel-
JuSo cell lines, the cells were pulsed with 35S-Cys/Met proteases, we incubated cells with the iodinated active-
site-directed probes 125I-MuTyrAlaCH2F and 125I-JPM-for 30 min and chased for 1, 2, 3 and 4 hr. Class II-Ii
complexes were isolated by immunoprecipitation with 565-OEt (Morton et al.,1995; Bogyo et al., 2000) known
to react selectively with most papain-related lysosomalthe HLA class II-specific mAb, DA6.231, and Ii was then
reimmunoprecipitated using the VICY1 mAb. As shown cysteine proteases. As previously described (Bogyo et
al., 2000) and shown in Figure 5B, 125I-JPM-565-OEt (topin Figure 4A, in the presence of doxycycline a rather
diffuse set of Ii products appeared during the chase panel) labeled a number of bands presumed to be lyso-
somal cysteine proteases. For example, cathepsin S canmigrating between 22–25 kDa (Pieters et al., 1991). In
contrast, when AEP was overexpressed, a more distinct be identified due to the fact that preincubation of the
cells with LHVS led to a selective loss of labeling (Riese22 kDa intermediate was generated (Figure 4A) which
was more pronounced when leupeptin was included to et al., 1996, and Figure 5B, track 5). Leupeptin pretreat-
ment also resulted in loss of cathepsin S labeling andisolate the initial stages of Ii processing (data not
shown). In addition, faster p31 processing was observed almost complete loss of a band migrating immediately
above it which is assumed to be cathepsin B (track 4).in cells overexpressing AEP (Figure 4B and compare
the p31/p22 ratio at the 2 and 3 hr time points). Note 125I-MuTyrAlaCH2F only labeled cathepsin S and B, and
this was abolished by leupeptin treatment and, in thethat the increase in p31 precipitation seen after 1 hr of
chase is due to an excess of p31 made during the pulse case of cathepsin S, by LHVS treatment. In contrast,
exposure of cells to MV026630 did not block the labelingassociating with unlabeled  and  chains during the
chase. Faster p31 processing in AEP overexpressing of cathepsins by either of the two active-site-directed
probes (Figure 5B, compare track 1 with tracks 2 andcells diminishes this increase. Thus, overexpression of
AEP accelerates p31 to p22 processing in MelJuSo cells. 3). We conclude that MV026630 specifically blocks the
AEP protease but not other lysosomal cysteine pro-
teases.Specific Inhibition of AEP Slows Down Ii Processing
in Professional APC We then tested the effect of the AEP inhibitor on Ii
degradation. PALA cells were preincubated withWe next tested the effect of inhibiting AEP in human B
cell lines and dendritic cells. We took advantage of a MV026630 for 2 hr, pulsed for 30 min with 35S-Met/Cys,
and then chased for different times in the presence ofnewly generated acyloxymethylketone inhibitor of AEP
2,6-dimethyl-benzoic acid 3-benzyloxycarbonylamino- leupeptin with or without MV026630. In the control cells
the LIP fragment of 22 kDa appeared after 1 hr and4-carbamoyl-2-oxo-butyl ester (MV026630) that will be
more fully described elsewhere (K.L. et al., unpublished accumulated thereafter (Figure 5C). In cells preincu-
bated with MV026630, there was a pronounced delaydata). We first confirmed that in living cells MV026630
blocked AEP but not other proteases. EDR cells were in the appearance of the LIP fragment which was only
just detectable after 3 hr of chase (Figure 5C). A similarincubated with MV026630, and lysates were tested for
their ability to hydrolyse different fluorometric sub- striking block in p22 production was obtained (quanti-
tated by phosphoimaging) when a second EBV cell line,strates. As shown in Figure 5A, MV026630 treatment
inhibited hydrolysis of the AEP substrate Z-Ala-Ala-Asn- EDR, was pulse labeled and chased in the presence of
MV026630 over a 4 hr period (Figure 5D). We also testedNHMec but had no effect on hydrolysis of Z-Val-Val-Arg-
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Figure 5. Inhibition of AEP Activity Interferes with Ii Processing and SDS-Stable Dimer Formation in Human Antigen-Presenting Cells
(A) Lysates from EDR cells preincubated with leupeptin (1 mM), MV206630 (20 M), or LHVS (200 nM) were prepared and used to measure
hydrolytic activity remaining for the substrates indicated. MV026630 is abbreviated to MV in this figure.
(B) EDR cells were preincubated in the absence (track 1) or presence of MV026630 (20 or 50 M; tracks 2 and 3), leupeptin (track 4), or LHVS
(track 5). The active-site-directed probes 125I-JPM-565-OEt (top gel) or 125I- Mu-Tyr-Ala-CH2F (bottom gel) were added for 3 hr, and samples
were analyzed using SDS-PAGE.
(C) PALA cells were labeled with 35S-Met/Cys and chased for the indicated times in the presence of leupeptin (1 mM) with or without MV026630
(20 M). Lysates were then immunoprecipitated with DA6.231 mAb and analyzed by SDS-PAGE.
(D) Quantification of a similar experiment to that shown in (C) but performed in EDR cells with chase for up to 4 hr.
(E) EDR cells were labeled and chased in the absence or presence of leupeptin or MV026630 for the indicated times. Class II/Ii complexes
were immunoprecipitated with mAb DA6.231 and eluted for 30 min in SDS sample buffer at room temperature. SDS-resistant -peptide
dimers and  chain were quantitated and expressed as a ratio.
(F) Human monocyte-derived dendritic cells were labeled with 35S-Met/Cys and chased for different times in the absence or presence of
leupeptin (1 mM) with or without MV026630 (20 M) or vehicle (DMSO). Lysates were immunoprecipitated with DA6.231 mAb and separated
on 12% Bis-Tris Nupage gel.
the effect of inhibition of AEP on the formation of SDS- still generated but were of higher molecular weight (* in
Figure 5F), and the 22 kDa size product was essentiallystable  dimers, a frequently used measure of normal
MHC class II-peptide loading and maturation (Davidson absent (compare 2 and 3 hr time points in Figure 5F).
Overall, our data demonstrate that AEP is the enzymeet al., 1991; Germain and Hendrix, 1991). As shown in
Figure 5E, SDS-stable dimers accumulated during a that generates the 22 kDa Ii processing product seen
in the presence of leupeptin. However, other processingchase following 35S-pulse labeling of EDR cells.
MV026630 clearly had an inhibitory effect on dimer for- activities continue to degrade Ii, and this is particularly
evident in DC.mation and/or stability though not as great as leupeptin.
Taken together, these results show that AEP is the en-
zyme acting on the intact Ii substrate to generate the Presentation of flu HA epitope (306-318) to Specific T
Cells Is Decreased When Ii Processing Is Impairedp22 LIP product and that inhibition of AEP causes a
measurable reduction in the appearance of fully mature We performed a further series of experiments in Mel-
JuSo cells to test the possibility that inhibition of AEPSDS-stable  dimers.
We also tested the effect of inhibiting AEP on Ii pro- processing of Ii would slow down the arrival of newly
synthesized MHC class II molecules on the cell surface.cessing in human dendritic cells (DC). Immature mono-
cyte-derived DC were preincubated with MV026630, and To do this, we took advantage of an Ii construct where
the CLIP peptide was replaced (Figure 6A) with the flunewly synthesized MHC class II molecules were pulse
labeled as before followed by a chase in the absence HA epitope 306-318 (Stumptner and Benaroch, 1997).
This HA/Ii construct is processed like the Ii chain, andor presence of leupeptin with or without MV026630. The
monocyte-derived DC showed essentially the same ki- the HA peptide which remains associated with HLA-DR1
molecules can be presented to the HA-specific T cellnetics of appearance in Ii processing products although
the size range of the leupeptin-induced products was line THA1.7 (Vincent-Schneider et al., 2001). We mutated
Asn residues 132 and 155 to Gln and first establishedclearly broader compared with EBV-B cells (Figure 5F).
In the presence of the AEP inhibitor, Ii products were that the mutated HA/Ii associated with HLA-DR1 class
Immunity
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Figure 6. Mutating AEP Cleavage Sites on a
flu HA/Ii Construct Delays the Appearance
of MHC Class II/HA Complexes at the Cell
Surface
(A) Schematic of the HA/Ii construct used.
Arrows indicate Asn sites that were mutated.
(B) MelJuSo cells transiently transfected with
DR1 cDNA and increasing concentrations
of cDNAs coding for HA/Ii wild-type (HA/N,
black bars) or mutated HA/Ii (HA/N132, 155Q,
white bars) were incubated with HA-specific
T cells for 24 hr. Supernatants were assayed
for IL-2.
(C) MelJuSo cells transfected with DR1 and
mutant or wild-type HA/Ii as in (B) were prein-
cubated with the following inhibitors: leupep-
tin (1 mM), AEPi (MV026630, 20 M), or leupeptin  AEPi and cocultured with HA-specific T cells. MelJuSo cells transfected with mutant
HA/Ii (HA/Q) were pulsed with 0.5 mM of HA peptide (306-318) and incubated with HA-specific T cells for 24 hr.
II molecules as well as wild-type HA/Ii (data not shown). teine proteases. Their identity, however, has never been
established.To test whether mutating AEP sites on HA/Ii chain would
Maric et al. provided evidence that specific asparticaffect the presentation of the HA peptide, MelJuSo cells
protease inhibitors blocked Ii degradation and MHCwere cotransfected with increasing amounts of cDNA
class II maturation in human B cells (Maric et al., 1994).of DR1*0101 plus HA/Ii wild-type (HA/N) or HA/Ii mutant
However, Riese et al., using similar cells, found that(HA/Q) cDNA. Presentation of the HA epitope was moni-
specific inhibition of cathepsin D with a different com-tored by IL-2 release from the HA-specific T cell hybrid-
pound did not result in accumulation of Ii fragments noroma THA1.7. As shown in Figure 6B, there was a clear
did it produce a decrease in SDS-stable MHC class IIdelay in the presentation of the HA peptide when the
complexes (Riese et al., 1996). Furthermore, spleen cellsHA/Q construct was used compared with the HA/N
from cathepsin D knockout mice did not show any alter-construct. This decrease in antigen presentation was
ation in the degradation of the Ii chain (Villadangos et al.,dependent on the amount of DNA transfected and, as
1997). Altogether, these results suggest that cathepsin Dexpected, was partially overcome when high concen-
is not essential for Ii processing but do not exclude atrations were used. Furthermore, if MelJuSo cell lines
possible role for a related aspartic protease.transfected with HA/N were incubated with MV026630,
We identify here a protease that initiates invariantpresentation was diminished to a comparable extent
chain processing. AEP is a cysteine protease but isproviding independent confirmation that AEP pro-
insensitive to leupeptin (Chen et al., 1997). Using lyso-cessing releases the class II/HA peptide complexes to
somal fractions purified from EBV B cells as a sourcethe cell surface (Figure 6C). As expected, leupeptin
of proteases to digest Ii, we show that AEP is the majoralone or in combination with MV026630 also decreased
activity able to cleave Ii. Specific inhibition of AEP, over-presentation to T cells (Figure 6C). Inhibition of HA pre-
expression of its activity, or mutation of AEP cleavagesentation by cells transfected with the HA/Q construct
sites on Ii shows that in living cells AEP is involved incould be restored when the HA peptide (306-318) was
initiating Ii processing. Moreover, the sites targeted byadded in the antigen presentation assay (Figure 6C).
AEP in vitro would generate fragments of 10 and 22 kDaThus, mutating AEP cleavage sites or blocking AEP ac-
in the mouse and human Ii, respectively, if they aretivity can slow down the rate of expression of MHC class
recognized in vivo. In other words, the intermediatesII molecules as measured with the HA/Ii probe.
induced by leupeptin treatment could be generated by
AEP. Consistent with this, the appearance of the LIP
Discussion p22 Ii product was almost completely abolished by inhi-
bition of AEP activity in human B cells. Furthermore,
Proteolytic processing of Ii is a critical determinant of mutating AEP cleavage sites on a form of the invariant
the timing and location of MHC class II peptide loading. chain where the CLIP peptide was replaced with the flu
While recent work has elucidated the terminal stages of HA epitope (306-318) induced a delay in the appearance
Ii processing, little information exists on how Ii pro- of MHC class II/HA complexes at the cell surface.
cessing is initiated. A key early study showed that in The strict specificity of AEP has allowed us to identify
the presence of the broad spectrum cysteine protease and mutate protease cleavage sites in the invariant chain
inhibitor leupeptin, a 22 kDa intermediate of human Ii for the first time. Although a complete 3D structure for
accumulated (Blum and Cresswell, 1988). In murine B Ii is not known, structural information is available for
cells expressing MHC class II molecules of the d or b the domain that mediates the trimerization of human Ii
haplotypes, leupeptin induces instead the accumulation (residues 118–192; Bijlmakers et al., 1994b; Jasanoff
of a 10 kDa product (Amigorena et al., 1995; Brachet et et al., 1998). Of the four Asn residues found on each
al., 1997). A similar leupeptin-induced product (10–12 protomer of the trimer, one (N120) is glycosylated (Ma-
kDa) can also be seen in some human cell lines (Maric chamer and Cresswell., 1982) and cannot be a target
et al., 1994). It has always been assumed that these for AEP. The remaining three are found on helices A and
B which surround the central core of C helices in theleupeptin-induced products are generated by noncys-
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N119. Both in vitro AEP digestion and mutagenesis stud-
ies confirm that this site is attacked by AEP. Although
we observed slowing down of the appearance of p10
when N105 alone was mutated, the most efficient block-
ade of the appearance of this leupeptin-induced product
was obtained when downstream Asn residues were also
mutated, suggesting that efficient cleavage at Asn105
requires prior upstream AEP cleavage, probably at N153
in the trimerization region. Mutagenesis of the N105 and
upstream sites did not completely block the appearance
of the p10 fragment. This suggests that an alternative
but less favored cleavage site for another enzyme is
also located in this region. This is consistent with the
fact that the human Ii, which does not have an Asn
residue in this position, can sometimes be processed
to give a similar sized intermediate, for example, in PALAFigure 7. AEP Processing Sites on the Human Ii Trimer
cells (Riberdy et al., 1994; Pond and Watts., 1999). ThisFigure generated from coordinates deposited by Jasanoff et al.
(1998) for Ii residues 118–192. Only residues 123–177 are shown for may be the same as the small leupeptin-induced Ii prod-
clarity. Each copy of the Ii trimerization region contributes an inner uct seen in some studies (Maric et al., 1994), suggesting
(C) helix and outer (A and B) helices. The AEP processing site at that the enzyme responsible may be a leupeptin-insensi-
Asn155 is shown by contrasting shading on each ribbon as is the tive enzyme other than AEP. Finally, although we foundpresumptive site at Asn132.
some evidence for an AEP cleavage at N76 (N-terminal
to the CLIP region) in human Ii, the persistence of the
p10 fragment containing this site in the presence of astructure of Jasanoff et al., which is also shown in Figure
catS inhibitor (Riese et al., 1996) indicates that it cannot7 (residues 123–177). However, N149 faces inward at
be efficiently recognized by AEP in living cells. This sitethe N-terminal end of helix B and is unlikely to be acces-
is in any case altered to Ser in mouse Ii.sible to AEP in the intact trimer. N155, located at the
Although AEP is involved in both human and murine IiC-terminal end of helix B, faces outward (Figure 7), and
processing, our studies to date do not reveal an absoluteindeed we find that the N155/T156 bond is readily
requirement for this enzyme in initiating p31 processingcleaved. We cannot be certain whether or not N132,
and MHC class II maturation. Human B lymphoblastoidlocated at the C-terminal end of helix A, is also cleaved.
cells treated with the MV026630 inhibitor of AEP for 24It is located on the outside of this helix as shown in
or 48 hr showed essentially the same steady-state levelFigure 7, but radiosequencing would not easily have
of surface MHC class II molecules (data not shown).identified this cleavage product since the nearest la-
This is similar to what was observed in cells from catSbeled residue is Met157, 25 residues downstream and
null mice where steady-state MHC class II levels were
past the 155 cleavage site. Assuming that N132 is also
essentially normal (Shi et al., 1999; Nakagawa et al.,
an AEP target, it is clear that there are Asn residues
1999). Apparently, blockade, even of key proteolytic en-
placed at precisely the right positions to attack the outer
zymes involved in Ii processing, can eventually be over-
helices of the Ii trimer (Figure 7). AEP cleavage at either come by the action of other enzymes. Redundancy
N132 or N155 would separate the p22/ products from might be predicted to be greatest at the earliest stages
the central core of C helices which appear crucial for of Ii processing. Once processing has reached the p10
trimer stability (Jasanoff et al., 1998). In spite of this, stage, the target for protease action is much smaller and
both p22/ and p10/ complexes retain the nonam- to a significant extent unavailable due to sequestration
eric configurations found in intact Ii/ (Newcomb and within either the peptide binding groove or the mem-
Cresswell., 1993; Amigorena et al., 1995). This may be brane barrier.
explained by the fact that the transmembrane domain Interestingly, even in the combined presence of
of Ii also plays an important role in trimerization (Ashman MV026630 and leupeptin some p31 processing still oc-
and Miller., 1999). curred, suggesting that in human B cells and dendritic
In the mouse, N149 and N155 are conserved. There cells other still unidentified enzymes can act on the
is an additional Asn in murine Ii at position 178, which intact invariant chain substrate. Removal of the invariant
in the human trimer structure is at the end of the central chain in the endocytic pathway of antigen-presenting
C helix, i.e., in the core of the trimer. It seems unlikely cells is as crucial as its presence is in the secretory
that this is a good AEP target, at least in the intact trimer. pathway perhaps dictating that intact Ii/MHC class II
Blockade of Ii processing with leupeptin is well known complexes may be sensitive to several proteases. We
to induce the accumulation of a smaller fragment of believe that the dominant p31-processing activities will
about 10 kDa in size (Amigorena et al., 1995) in several vary depending on the APC in question. In B cells and
mouse MHC class II haplotypes, although a p22 frag- thymic APCs (Manoury et al., 2002), AEP may play a
ment can also sometimes be seen (Villadangos et al., major role since it is a prominent activity. In other cell
1997). The predominance of the murine p10 Ii intermedi- types it may be less important. For example, we have
ate can be explained by the presence of an additional found variable but generally lower levels of expression
Asn residue in the murine Ii chain at position 105 (Ala106 of AEP in human monocyte-derived dendritic cells com-
in human Ii). This residue is located between the CLIP pared with EBV B cells (C. Moss and B.M, unpublished
data). This could explain why, in the presence of leupep-region and the two N-glycosylation sites at N113 and
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antisense primer CAC GCC ATC TAC AGG CTG GTT AAG ATG CTTtin, a relatively indistinct p22 product is seen compared
C; Asn159, sense primer CC ATG GAT GGC GTG CAG TGG AAGwith B cells. Instead, a rather broad set of Ii processing
ATC TTC G, antisense primer C AAG GAT CTT CCA CTG CAG GCCproducts was observed between 22 and 25 kDa. Inhibi-
ATC CAT GG; Asn178 sense primer GAG ATG AGC AAG CAG TCC
tion of AEP under these conditions eliminates the ap- CTG GAG GAG AAG, antisense primer CTT CTC CTC CAG GGA
pearance of the fragments in the 22 kDa region but not CTG CTT GCT CAT CTC. For human Ii chain: Asn132, sense primer
G CAC CTG CTC CAG CAA GCT GAC CCC CTG AAG G, antisensethe larger ones. Combined use of leupeptin and the
primer C CTT CAG GGG GTC AGC TTG CTG GAG CAG GTG C;AEP inhibitor in B cells also led to the appearance of Ii
Asn155, sense primer G AGA CAC CTT AAG CAG ACC ATG GAGfragments in the 25 kDa range. The situation is some-
ACC ATA G, antisense primer C TCT GGT CTC CAT GGT CTG CTTwhat similar to that seen in MelJuSo cells in the absence
AAG GTG TCT C.
of AEP overexpression (compare Figures 4A and 5F,
and data not shown). Taken together, the data point
Pulse-Chase, Immunoprecipitation, and Radiolabelingto the existence of at least one additional leupeptin-
of Peptide Inhibitorsinsensitive enzyme acting at the earliest stages of Ii
CHO, COS, LB27.4, MelJuSo, and human EBV-B cells were preincu-processing. It is possible that this is an aspartic protease
bated in Met/Cys-free RPMI 1640 medium for 2 hr. Cells (106 ) were
as suggested by the data of Maric et al. (1994). Thus, then pulsed for 30 min with 0.5 mCi of 35S-Met/Cys (ICN) and chased
multiple enzymes are capable of initiating Ii processing. in unlabeled medium supplemented with 5 mM cold methionine in
This situation is similar to the terminal stages of Ii pro- the presence or absence of different inhibitors for the indicated
times. Cells were then lysed in a buffer containing 20 mM Tris-HClcessing where different cathepsins perform this step in
(pH 7.5), 150 mM NaCl, 2 mM MgCl2, 1% Triton X-100, and andifferent cell types (Nakagawa et al., 1998, 1999; Shi et
inhibitor cocktail (Roche). Each sample was normalized either foral., 1999, 2000). In addition, the protease requirements
the same number of cells or for equivalent protein in the case of
for Ii removal vary among different MHC class II haplo- COS and CHO transfectants. Lysates were precleared with human
types in the mouse (Villadangos et al., 1997; Nakagawa or mouse serum, and MHC class II/Ii complexes were recovered by
et al., 1999). Thus far, we have only explored the AEP immunoprecipitation with the following antibodies: M5/114, Y3P for
mouse or DA6.231 for human. For reprecipitation of MHC class II-requirement for Ii processing in cells transfected with
associated Ii molecules, washed DA6.231 or M5/114 immunoprecip-the d and b haplotypes. Ii processing was compromised
itates were resuspended in 50 l phosphate buffer saline/1% SDSin both when AEP sites were mutated but ablation of
and incubated at 95C for 10 min. The eluted proteins were diluted
AEP activity in professional APC of different murine hap- into 1 ml of lysis buffer, and Ii molecules were immunoprecipitated
lotypes will be needed to fully assess this. using mAbs IN1 for mouse or VICY1 for human. Samples were boiled
Several of the cysteine proteases shown originally to in sample buffer and separated by 12% SDS-PAGE (Novex). Quanti-
fication of the results was made using a phosphoimager (Fuji). Reac-play a role in Ii processing, such as cathepsins S and
tive cysteine protease inhibitors (MuTyrAlaCH2F and JPM-565-OEt)L, have recently been shown to be required for genera-
were iodinated using the reported protocol (Xing et al., 1998; Bogyotion of specific peptides during antigen processing
et al., 2000). In brief, the reagants were labeled with 20 g Iodogen
(Hsieh et al., 2002; Pluger et al., 2002). In addition, a dried onto the bottom of a glass tube in 10 l of 0.25 M phosphate
potential role for cathepsin L in the generation of pep- buffer (pH 7.5) to which was added 10 M Mu-Tyr-Ala-CH2F (1.25
tides for positive selection of CD4 T cells by cortical l) or JPM-565-OEt (2.5l) followed by 0.5 mCi (5l) of 125I-Na (Amer-
sham). The reaction was incubated for 10 min on ice and stoppedthymic epithelial cells was recently described (Honey et
by the addition of 2 l of 20 mM tyramine and 1l of 1 M KI. Theal., 2002). In contrast, AEP, first described as a protease
volume of the reaction was adjusted to 0.5 ml with 0.5 M phosphaterequired for antigen processing, emerges as a key par-
buffer (pH 7.5), and the labeled reagent was used without further
ticipant in Ii processing as well. The developing picture is purification. The cells (5  105 ) were incubated with 50 nM of either
one where most of the major enzymes in the endosome probe, washed, lysed, and clarified by centrifugation (2200 rpm for
system of antigen-presenting cells participate in both 10 min) prior to analysis of supernatents by 14% SDS-PAGE.
of these crucial proteolytic events.
Site-Directed Mutagenesis
Experimental Procedures The human and mouse invariant chain and the HA/Ii cDNAs (Stumpt-
ner and Benaroch, 1997) were cloned into and mutated in plasmid
Peptides, Oligonucleotides, and Antibodies pcDNA3 using the QuikChange Mutagenesis Kit (Stratagene) ac-
AENK and AEQK tetrapeptides were used as described (Manoury et cording to the manufacturer’s conditions. Positive colonies which
al., 1998). AEP was purified from pig kidney essentially as described contained the desired mutations were then grown in 150 ml of LB
(Chen et al., 1997). Leupeptin was obtained from Sigma and cystatin supplemented with ampicillin (100 g/ml), and DNA was extracted
C from Calbiochem. Morpholine urea-Tyr-Ala-CH2 F (Mu-Tyr-Ala- using the endotoxin-free Maxiprep kit (Qiagen). Purified DNA was
CH2F), JPM-565-OEt, and morpholineurea-leucinyl-homophenylala- then used to transiently transfect CHO, COS, or MelJuSo cells using
nine-vinylsulfone-phenyl (LHVS) were generous gifts from Drs. P. a standard calcium phosphate protocol (Knight et al., 1997).
Morton, M. Bogyo, and H. Ploegh, respectively. MV026630 is an
acyloxymethyl ketone inhibitor of AEP that will be more fully de-
scribed elsewhere. Stock solutions of inhibitors were prepared in Fluorometric Assays and Inhibitors
EBV-B cells were incubated with 1 mM leupeptin (Sigma) or 20 MDMSO or water. The HA306-318 peptide (PKYVKQNTLKLAT) was
synthesized by Synt:em (Nimes, France). cDNAs for mouse Ii chain of the AEP inhibitor 2,6-dimethyl-benzoic acid 3-benzyloxycarbon-
ylamino-4-carbamoyl-2-oxo-butyl ester (MV026630) for 24 or 48 hrand for  and  chains of I-Ab and I-Ad were gifts from Drs. P.
Pierre and R. Germain, respectively. DR1* was subcloned from the and then lysed in 50 mM sodium citrate buffer (pH 5.5), 5 mM DTT,
0.1% CHAPS, and 0.5% Triton X-100. Protein content was determinedplasmid pSP72-DR1 (Biljmakers et al., 1994) into the EcoRV/XhoI
sites of the pcDNA3 plasmid (Invitrogen). Oligonucleotides were using a BCA assay (Pierce). Postnuclear lysates were incubated
with 40M of the following protease substrates (Z-Phe-Arg-NHmec,custom synthesized by MWG Biotech. The following primers were
used. For mutagenesis of mouse Ii chain: Asn105, sense primer CCA Z-Val-Val-Arg-NHmec, Z-Ala-Ala-Asn-NHmec; preferentially cleaved
by catB/L, catS, and AEP, respectively) for 30 min. Release ofATG TCC ATG GAT CAG ATG CTC CTT GGG C, antisense primer
GCC CAA GGA GCA TCT GAT CCA TGG ACA TGG G; Asn153, 7-amido-4-methyl coumarin was measured on a Cytofluor 4000 Flu-
orimeter (Applied Biosystems).sense primer G AAG CAT CTT AAG CAG TCC ATG GAT GGC GTG,
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In Vitro Digestion and Radio Sequencing domain in the trimerization of the MHC class II-associated invariant
chain. J. Immunol. 163, 2704–2712.Lysosomal fractions from the human B cell line EDR or the monocytic
cell line HL-60 were prepared on 27% Percoll density gradient as Bakke, O., and Dobberstein, B. (1990). MHC class II-associated
described (Davidson et al., 1990) using -hexosaminidase activity invariant chain contains a sorting signal for endosomal compart-
to identify lysosomal fractions. Radiolabeled Ii chain was digested ments. Cell 63, 707–716.
with lysosomal membranes (5 g) or pig kidney AEP (mU as indi-
Bijlmakers, M.J., Benaroch, P., and Ploegh, H.L. (1994a). Assembly
cated) in 20 l 50 mM sodium citrate buffer (pH 5.5), 5 mM DTT,
of HLA DR1 molecules translated in vitro: binding of peptide in the
0.1% CHAPS in the presence or absence of the inhibitors: leupeptin
endoplasmic reticulum precludes association with invariant chain.
(100 g/ml), cystatin C (100 g/ml), AENK, or AEQK peptide (1 mg/
EMBO J. 13, 2699–2707.
ml) for 1 hr. The reactions were separated on Nupage Bis-Tris gels
Bijlmakers, M.J., Benaroch, P., and Ploegh, H.L. (1994b). Mapping(Novex). In some experiments, labeled digestion products were
functional regions in the lumenal domain of the class II-associatedtransferred to nitrocellulose and subjected to 20 cycles of Edman
invariant chain. J. Exp. Med. 180, 623–629.degradation. The PTH derivatives obtained from each cycle were
Blum, J.S., and Cresswell, P. (1988). Role for intracellular proteasesanalyzed by scintillation counting.
in the processing and transport of class II HLA antigens. Proc. Natl.
Acad. Sci. USA 85, 3975–3979.Cell Culture and Antigen Presentation Assay
The human EBV-B cell lines (EDR and PALA) and mouse B cell Bogyo, M., Verhelst, S., Bellingard-Dubouchaud, V., Toba, S., and
(LB27.4) were maintained in RPMI 1640 medium supplemented with Greenbaum, D. (2000). Selective targeting of lysosomal cysteine
2 mM L-glutamine, 5  105 M 2-mercaptoethanol, 100 U/ml of proteases with radiolabeled electrophilic substrate analogs. Chem.
penicillin, 100 g/ml of streptomycin, 10% fetal calf serum (all from Biol. 7, 27–38.
Life Technologies). DMEM medium was used to grow CHO, COS, Brachet, V., Raposo, G., Amigorena, S., and Mellman, I. (1997). Ii
or MelJuSo cells. Monocyte-derived dendritic cells were prepared chain controls the transport of major histocompatibility complex
essentially as described (Sallusto and Lanzavecchia, 1994) but using class II molecules to and from lysosomes. J. Cell Biol. 137, 51–65.
MACS CD14 beads (Miltenyi Biotec) to isolate monocyte precur-
Busch, R., Cloutier, I., Sekaly, R.P., and Hammerling, G.J. (1996).
sors. MelJuSo cells were transiently transfected using a standard
Invariant chain protects class II histocompatibility antigens from
calcium phosphate protocol (Knight et al., 1997) with HLA-DR1
binding intact polypeptides in the endoplasmic reticulum. EMBO J.
cDNA (1 g/well) and increasing amounts of wild-type (HA/N) or
15, 418–428.
mutated (HA/Q) cDNA. Forty hours later, the cells were detached
Chen, J.M., Rawlings, N.D., Stevens, R.A.E., and Barrett, A.J. (1998).with PBS/EDTA, counted, and plated in 96-well plates at a density
Identification of the active site of legumain links it to caspases,of 105 cells per well. Inhibitors were added to the antigen-presenting
clostripain and gingipains in a new clan of cystein endopeptidases.cells 16 hr before they were harvested, and the cells were further
FEBS Lett. 441, 361–365.incubated in the presence of inhibitors for 4 hr. The cells were then
extensively washed and cultured with the HA-specific T cell line Chen, J.M., Dando, P.M., Rawlings, N.D., Brown, M.A., Young, N.E.,
Stevens, R.A., Hewitt, E., Watts, C., and Barrett, A.J. (1997). Cloning,THA1.7 (Hewitt et al., 1992). 5  104 T cells were used in a 24 hr
assay. Fresh or frozen supernatants were tested for the presence of isolation, and characterization of mammalian legumain, an asparagi-
nyl endopeptidase. J. Biol. Chem. 272, 8090–8098.IL-2 using an enzyme-linked immunosorbent assay kit (Pharmingen).
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